Skip to main content

West Pharmaceutical Services guidance

  • WST · NYSE
  • Medical devices
  • Health Care Supplies
  • S&P 500
$418.17+0.09%Close 17 Nov 2026 · Market value $28.97B

In its results release of 29 Oct 2026 (Q3 FY2026), West Pharmaceutical Services gave 2 forecasts in figures, among them EPS (adjusted) of $9.38 to $9.48 for FY2026. Over the last two years, results landed above the company's own last range 10 of 13 times, within it 2 and below it 1.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 29 Oct 2026

MeasurePeriodGuidanceAs stated
EPS · Adjusted · RaisedFY2026$9.38 to $9.48The Company is increasing its full-year 2026 adjusted-diluted EPS guidance range to $9.38 to $9.48, up from the previous range of $8.85 to $9.05.
Capital expendituresFY2026$215M to $220MFull-year 2026 capital spending guidance is updated to a range of $215 million to $220 million, down from the prior range of $250 million to $275 million.

Source: the company's earnings release.

Guidance against results above 10 · within 2 · below 1

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$3.35B to $3.38BRaised once—To come
Revenue growthFY2026+8.8% to +10%Raised once—To come
Organic revenue growthFY2026+10% to +11%Raised once—To come
EPS · AdjustedFY2026$9.38 to $9.48Raised 3 times—To come
Capital expendituresFY2026$215M to $220MLowered once—To come
RevenueQ3 FY2026$820M to $835MGiven once$875MAbove the range
Revenue growthQ3 FY2026+1.9% to +3.8%Given once+8.69%Above the range
EPS · AdjustedQ3 FY2026$2.14 to $2.24Given once$2.66Above the range
RevenueQ2 FY2026$830M to $850MGiven once$872MAbove the range
Revenue growthQ2 FY2026+8.3% to +10.9%Given once+13.8%Above the range
EPS · AdjustedQ2 FY2026$2.05 to $2.12Given once$2.37Above the range
RevenueQ1 FY2026$770M to $790MGiven once$845MAbove the range
EPS · AdjustedQ1 FY2026$1.65 to $1.70Given once$2.13Above the range
RevenueFY2025$2.94B to $2.98BRaised once$3.07BAbove the range
Revenue growthFY2025+5.8% to +6.1%Given once+6.25%Above the range
Capital expendituresFY2025$275MGiven once$286MAbove the range
Tax rateFY2025About 21%Lowered once20.24%Below the range
Revenue growthQ4 FY2025+5.5% to +6.8%Given once+7.51%Above the range
EPS · AdjustedQ4 FY2025$1.81 to $1.86Given once$2.04Above the range
Tax rateQ4 FY2025About 21%Given once20.62%Within the range
RevenueFY2024$2.88B to $2.90BGiven once$2.89BWithin the range
Tax rateQ4 FY202422%Given once22.32%Above the range

WST in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.